trial · primary record
Atezolizumab
Ovarian Cancer
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2026-02-12 |
| Primary endpoint | Overall Response Rate as assessed by RECIST 1.1. |
| Registry ID | NCT03363867 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:42:50.755Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03363867
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Atezolizumab · compound